NewAmsterdam Pharma (NAMS) | Financial Analysis & Statements
Financial Overview
Latest Annual: 2024Income Metrics
Revenue
45.6M
Operating Income
-176.3M
-386.91%
Net Income
-241.6M
-530.25%
EPS (Diluted)
-$2.56
Balance Sheet Metrics
Total Assets
864.6M
Total Liabilities
107.1M
Shareholders Equity
757.5M
Debt to Equity
0.14
Cash Flow Metrics
Operating Cash Flow
-224.8M
Free Cash Flow
-159.2M
Revenue & Profitability Trend
NewAmsterdam Pharma Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 45.6M | 14.1M | 106.9M | 0 | 0 |
| Cost of Goods Sold | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | 221.9M | 189.2M | 104.9M | 36.1M | 6.8M |
| Operating Income | -176.3M | -175.1M | 2.0M | -36.1M | -6.8M |
| Pre-tax Income | -241.6M | -176.9M | -23.6M | -43.5M | -7.4M |
| Income Tax | -1.0K | 27.0K | 0 | 0 | 0 |
| Net Income | -241.6M | -176.9M | -23.6M | -43.5M | -7.4M |
| EPS (Diluted) | -$2.56 | -$2.15 | -$1.19 | -$0.51 | -$0.09 |
Income Statement Trend
NewAmsterdam Pharma Balance Sheet From 2021 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | 863.4M | 346.8M | 497.4M | 69.4M | 2.7T |
| Non-Current Assets | 1.2M | 306.0K | 539.1K | 1.1M | 10.2T |
| Total Assets | 864.6M | 347.1M | 498.0M | 70.4M | 12.9T |
| Liabilities | |||||
| Current Liabilities | 106.9M | 49.9M | 37.5M | 11.6M | 1.0T |
| Non-Current Liabilities | 202.0K | 8.8M | 12.9M | 130.8K | 5.2T |
| Total Liabilities | 107.1M | 58.7M | 50.4M | 11.8M | 6.3T |
| Equity | |||||
| Total Shareholders Equity | 757.5M | 288.4M | 447.6M | 58.7M | 3.2T |
Balance Sheet Composition
NewAmsterdam Pharma Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -241.6M | -176.9M | -23.6M | -43.5M | -7.4M |
| Operating Cash Flow | -224.8M | -155.9M | 13.1M | -28.0M | -6.9M |
| Investing Activities | |||||
| Capital Expenditures | -672.0K | -24.0K | -230.0K | -25.0K | -16.6K |
| Investing Cash Flow | -62.8M | -24.0K | 582.5K | -25.0K | -16.6K |
| Financing Activities | |||||
| Dividends Paid | - | - | - | - | - |
| Financing Cash Flow | 644.0M | 0 | 407.8M | 88.1M | 14.5M |
| Free Cash Flow | -159.2M | -141.2M | 10.9M | -30.7M | -7.7M |
Cash Flow Trend
NewAmsterdam Pharma Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-7.19
Forward P/E
-9.63
Price to Book
2.63
Price to Sales
43.37
PEG Ratio
-9.63
Profitability Ratios
Profit Margin
0.00%
Operating Margin
-2,314.47%
Return on Equity
-31.51%
Return on Assets
-18.15%
Financial Health
Current Ratio
19.98
Debt to Equity
0.05
Beta
-0.02
Per Share Data
EPS (TTM)
-$1.84
Book Value per Share
$6.93
Revenue per Share
$0.47
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| nams | 2.0B | -7.19 | 2.63 | -31.51% | 0.00% | 0.05 |
| Vertex | 114.1B | 32.82 | 6.92 | -5.64% | -8.91% | 10.00 |
| Regeneron | 55.3B | 13.02 | 1.84 | 15.96% | 31.94% | 9.20 |
| Blueprint Medicines | 8.3B | -120.00 | 24.19 | -47.71% | -27.70% | 208.50 |
| Roivant Sciences | 7.8B | 1.95 | 1.71 | -12.54% | 96.86% | 1.93 |
| Bio-Techne | 7.9B | 60.87 | 3.92 | 6.53% | 10.89% | 20.99 |
Financial data is updated regularly. All figures are in the company's reporting currency.